Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,... – Structurally-modified antibody – immunoglobulin – or fragment...
Reexamination Certificate
2004-12-03
2009-11-24
Mosher, Mary E (Department: 1648)
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
Structurally-modified antibody, immunoglobulin, or fragment...
C424S141100, C424S141100, C424S147100, C424S009100, C530S387300, C530S388100, C435S328000, C435S339000, C435S252300, C435S005000, C536S023530
Reexamination Certificate
active
07622113
ABSTRACT:
The present invention relates to monoclonal antibodies that bind or neutralize dengue type 1, 2, 3, and/or 4 virus. The invention provides such antibodies, fragments of such antibodies retaining dengue virus-binding ability, fully human or humanized antibodies retaining dengue virus-binding ability, and pharmaceutical compositions including such antibodies. The invention further provides for isolated nucleic acids encoding the antibodies of the invention and host cells transformed therewith. Additionally, the invention provides for prophylactic, therapeutic, and diagnostic methods employing the antibodies and nucleic acids of the invention.
REFERENCES:
patent: 6184024 (2001-02-01), Lai et al.
patent: 7282205 (2007-10-01), Schofield et al.
patent: WO 99/55369 (1999-11-01), None
Pupo-Antunez et al. Hybridoma 20:35-41, 2001.
Kellerman et al. Current Opinion in BIotechnology 13:593-597, 2002.
Paul, Fundamental Immunology, (textbook), 1993, pp. 292-295. Lippincott-Raven Publishers, Philadelphai, PA.
Pupo-Antunez et al (Hybridoma 20:35-42, 2001).
Gavilondo et al (BioTechniques 29:128-145, 2000).
Scherer et al (American Journal of Tropical Medicine and Hygiene 27:590-599, 1978, abstract only cited).
Sanna et al (Immunotechnology 4:185-188, 1999).
Men et al, Journal of Virology 78:4665-4674, 2004.
Allen, J.M. et al. (1989) “Isolation and expression of functional high-affinity Fc receptor complementary DNAs.”Science243:378-381.
Ames, R.S. et al. (1995) “Conversion of murine fabs isolated from a combinatorial phage display library to full length immunoglobulins”J. Immunol. Methods184:177-186.
Armour, K.L. et al. (1999) “Recombinant human IgG molecules lacking Fcγ receptor I binding and monocyte triggering activities”Eur. J. Immunol. 29:2613-2624.
Barbas, C.F. et al. (1991) “Assembly of combinatorial antibody libraries on phage surfaces: the gene III site.”PNAS USA88:7978-7982.
Barbas, C.F. et al. (1994) “In vitro evolution of a neutralizing human antibody to human immunodeficiency virus type 1 to enhance affinity and broaden strain cross reactivity.”PNAS USA91:3809-3813.
Brandriss, M.W. et al. (1986) “Lethal 17D yellow fever encephalitis in mice. I. Passive protection by monoclonal antibodies to the envelope proteins of 17D yellow fever and dengue 2 viruses.”J. Gen. Virol. 67:229-234.
Bray, M. et al. (1991) “Dengue virus premembrane and membrane proteins elicit a protective immune response.”Virology185:505-508.
Burton, D.R. et al. (1994) “Efficient neutralization of primary isolates of HIV-1 by a recombinant human monoclonal antibody”Science266:1024-1027.
Chambers, T.J. et al. (1990) “Flavivirus genome organization, expression, and replication”Annu. Rev. Microbiol. 44:649-688.
Chappel, M.S. et al. (1991) “Identification of the Fcγ receptor class I binding site in human IgG through the use of recombinant IgG1/IgG2 hybrid and point-mutated antibodies.”PNAS USA88:9036-9040.
Cox, J.P. et al. (1994) “A directory of human germ-line Vκ segments reveals a strong bias in their usage.”Eur. J. Immunol. 24:827-836.
Crowe, J.E., Jr. et al. (1994) “Recombinant human respiratory syncytial virus (RSV) monoclonal antibody Fab is effective therapeutically when introduced directly into the lungs of RSV-infected mice.”PNAS USA91:1386-1390.
Doral H. et al. (1987) “The effect of dihydrofolate reductase-mediated gene amplification on the expression of transfected immunoglobulin genes.”J. Immunol. 139:4232-4241.
Durbin, A.P. et al. (2001) “Attenuation and immunogenicity in humans of a live dengue virus type 4 vaccine candidate with a 30 nucleotide deletion in its 3′ -untranslated region.”Am. J. Trop. Med. Hyg. 65:405-413.
Ehrlich, P.H. et al. (1988) “Further characterization of the fate of human monoclonal antibodies in rhesus monkeys.”Hybridoma7:385-395.
Ehrlich, P.H. et al. (1990) “Potential of primate monoclonal antibodies to substitute for human antibodies: nucleotide sequence of chimpanzee Fab fragments.”Hum. Antib. Hybrid. 1:23-26.
Ehrlich, P.H. et al. (1991) “Nucleotide sequence of chimpanzee Fc and hinge regions.”Mol. Immunol. 28:319-322.
Falgout, B. et al. (1990) “Immunization of mice with recombinant vaccinia virus expressing authentic dengue virus nonstructural protein NS1 protects against lethal dengue virus encephalitis.”J. Virol. 64:4356-4363.
Falgout, B. et al. (1991) “Both nonstructural proteins NS2B and NS3 are required for the proteolytic processing of dengue virus non-structural proteins.”J. Virol. 65:2467-2475.
Gentry, M.K. et al. 1982 “Identification of distinct antigenic determinants on dengue 2 virus using monoclonal antibodies.”Am. J. Trop. Med. Hyg. 31:548-555.
Glamann, J. et al. (1998) “Simian immunodeficiency virus (SIV) envelope-specific Fabs with high-level homologous neutralizing activity: recovery from a long-term-nonprogressor SIV-infected macaque.”J. Virol. 72:585-592.
Goncalvez, A.P. et al. (2004) “Chimpanzee fab fragments and a derived humanized immunoglobulin G1 antibody that efficiently cross-neutralize dengue type 1 and type 2 viruses.”J. Virol. 78:12910-12918.
Goncalvez, A.P. et al. (2004) “Epitope determinants of a chimpanzee Fab antibody that efficiently cross-neutralizes dengue type 1 and type 2 viruses map to inside and in close proximity to fusion loop of the dengue type 2 virus envelope glycoprotein.”J. Virol. 78:12919-12928.
Gould, E.A. et al. (1986) “Neutralizing (54K) and non-neutralizing (54K and 48K) monoclonal antibodies against structural and non-structural yellow fever virus proteins confer immunity in mice.”J. Gen. Virol. 67:591-595.
Halstead, S. (1982) “Immune enhancement of viral infection.”Prog. Allergy31:301-364.
Heinz, F.X. (1986) “Epitope mapping of flavivirus glycoproteins.”Adv. Virus Res. 31:103-168.
Heinz, F.X. et al. (1983) “A topological and functional model of epitopes on the structural glycoprotein of tick-borne encephalitis virus defined by monoclonal antibodies.”Virology126:525-537.
Heinz, F.X. et al. (1994) “Structural changes and functional control of the tick-borne encephalitis virus glycoprotein E by the heterodimeric association with protein prM.”Virology198:109-117.
Henchal, E.A. et al. (1982) “Dengue virus-specific and flavivirus group determinants identified with monoclonal antibodies by indirect immunofluorescence”Am. J. Trop. Med. Hyg. 31:830-836.
Henchal, E.A. et al. (1985) “Epitopic analysis of antigenic determinants on the surface of dengue 2 virion using monoclonal antibodies”Am. J. Trop. Med. Hyg. 34:162-169.
Henchal, E.A. et al. (1986) “Identification of an antigenic and genetic variant of dengue-4 virus from the Caribbean.”Am. J. Trop. Med. Hyg. 35:393-400.
Henchal, E.A. et al. (1988) “Synergistic interactions of anti-NS1 monoclonal antibodies protect passively immunized mice from lethal challenge with dengue 2 virus”J. Gen. Virol. 69:2101-2107.
Holzmann, H. et al. (1995) “Tick-borne encephalitis virus envelope protein E-specific monoclonal antibodies for the study of low pH-induced conformational changes and immature virions.”Arch. Virol.140:213-221.
Huber, C. et al. (1993) “The Vκ genes of the L regions and the repertoire of Vκ gene sequences in the human germ line.”Eur. J. Immunol. 23:2868-2875.
International Preliminary Report on Patentability from PCT/US2004/040674, Jun. 12, 2006.
Johnson, S. et al. (1997) “Development of a humanized monoclonal antibody (MEDI-493) with potent in vitro and in vivo activity against respiratory syncytial virus.”J. Infect. Dis. 176:1215-1224.
Kaufman, B.M. et al. (1987) “Monoclonal antibodies against dengue 2 virus E-glycoprotein protect mice against lethal dengu
Lai Ching-Juh
Purcell Robert H.
Corless Peter F.
Edwards Angell Palmer & & Dodge LLP
Mosher Mary E
The United States of America as represented by the Department of
LandOfFree
Monoclonal antibodies that bind or neutralize dengue virus does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Monoclonal antibodies that bind or neutralize dengue virus, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Monoclonal antibodies that bind or neutralize dengue virus will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4119977